BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37553183)

  • 1. Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation.
    Alshebremi M; Tomchuck SL; Myers JT; Kingsley DT; Eid S; Abiff M; Bonner M; Saab ST; Choi SH; Huang AY
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
    Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
    Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
    Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
    Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T
    Benoit-Lizon I; Jacquin E; Rivera Vargas T; Richard C; Roussey A; Dal Zuffo L; Martin T; Melis A; Vinokurova D; Shahoei SH; Baeza Garcia A; Pignol C; Giorgiutti S; Carapito R; Boidot R; Végran F; Flavell RA; Ryffel B; Nelson ER; Soulas-Sprauel P; Lawrence T; Apetoh L
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.
    Wilski NA; Stotesbury C; Del Casale C; Montoya B; Wong E; Sigal LJ; Snyder CM
    J Immunol; 2020 Jun; 204(11):2961-2972. PubMed ID: 32284333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
    Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
    Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
    Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research.
    Yu ZP; Sun XW; He YP; Gu J; Jin Y
    Int J Hyperthermia; 2023; 40(1):2164625. PubMed ID: 36966808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
    J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
    Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnitude of Therapeutic STING Activation Determines CD8
    Sivick KE; Desbien AL; Glickman LH; Reiner GL; Corrales L; Surh NH; Hudson TE; Vu UT; Francica BJ; Banda T; Katibah GE; Kanne DB; Leong JJ; Metchette K; Bruml JR; Ndubaku CO; McKenna JM; Feng Y; Zheng L; Bender SL; Cho CY; Leong ML; van Elsas A; Dubensky TW; McWhirter SM
    Cell Rep; 2018 Dec; 25(11):3074-3085.e5. PubMed ID: 30540940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
    Della Corte CM; Sen T; Gay CM; Ramkumar K; Diao L; Cardnell RJ; Rodriguez BL; Stewart CA; Papadimitrakopoulou VA; Gibson L; Fradette JJ; Wang Q; Fan Y; Peng DH; Negrao MV; Wistuba II; Fujimoto J; Solis Soto LM; Behrens C; Skoulidis F; Heymach JV; Wang J; Gibbons DL; Byers LA
    J Thorac Oncol; 2020 May; 15(5):777-791. PubMed ID: 32068166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
    Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
    Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Hepatocellular Carcinoma by Multimodal In Situ Vaccination Using Cryoablation and a Plant Virus Immunostimulant.
    Ghani MA; Bangar A; Yang Y; Jung E; Sauceda C; Mandt T; Shukla S; Webster NJG; Steinmetz NF; Newton IG
    J Vasc Interv Radiol; 2023 Jul; 34(7):1247-1257.e8. PubMed ID: 36997021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING.
    Tian J; Zhang D; Kurbatov V; Wang Q; Wang Y; Fang D; Wu L; Bosenberg M; Muzumdar MD; Khan S; Lu Q; Yan Q; Lu J
    EMBO J; 2021 Apr; 40(7):e106065. PubMed ID: 33615517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.